CN108441483B - 一种促进牛鼻气管炎病毒复制的方法 - Google Patents
一种促进牛鼻气管炎病毒复制的方法 Download PDFInfo
- Publication number
- CN108441483B CN108441483B CN201810377315.6A CN201810377315A CN108441483B CN 108441483 B CN108441483 B CN 108441483B CN 201810377315 A CN201810377315 A CN 201810377315A CN 108441483 B CN108441483 B CN 108441483B
- Authority
- CN
- China
- Prior art keywords
- bovine
- rhinotracheitis virus
- kidney cells
- bovine rhinotracheitis
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000001737 promoting effect Effects 0.000 title claims abstract description 15
- 230000029812 viral genome replication Effects 0.000 title claims abstract description 14
- 241000283690 Bos taurus Species 0.000 claims abstract description 27
- 210000003292 kidney cell Anatomy 0.000 claims abstract description 25
- 239000002609 medium Substances 0.000 claims abstract description 23
- 239000001963 growth medium Substances 0.000 claims abstract description 20
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims abstract description 15
- 230000001678 irradiating effect Effects 0.000 claims abstract description 10
- 238000011534 incubation Methods 0.000 claims abstract description 8
- 230000001276 controlling effect Effects 0.000 claims description 5
- 239000001307 helium Substances 0.000 claims description 4
- 229910052734 helium Inorganic materials 0.000 claims description 4
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000012091 fetal bovine serum Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 229960005486 vaccine Drugs 0.000 abstract description 11
- 230000010076 replication Effects 0.000 abstract description 5
- 230000002779 inactivation Effects 0.000 abstract description 3
- 239000006143 cell culture medium Substances 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 14
- 238000003753 real-time PCR Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000009832 plasma treatment Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 description 4
- 238000012257 pre-denaturation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000011053 TCID50 method Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/25—Urinary tract cells, renal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16751—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开了一种促进牛鼻气管炎病毒复制的方法，其包括用低温常压等离子体发生器照射牛肾细胞培养基，将经过照射处理的所述培养基加入牛肾细胞中，并加入牛鼻气管炎病毒孵育。本发明通过等离子体间接处理细胞，处理均匀且强度可控。本发明处理时间只需2min，操作简单、快速，处理后的DMEM培养基与牛鼻气管炎病毒和牛肾细胞一同孵育1h就能显著提高牛鼻气管炎病毒在牛肾细胞中的复制，得到的高浓度牛鼻气管炎病毒经灭活处理可用于疫苗生产，显著提高疫苗生产效率。
Description
技术领域
本发明属于疫苗生产技术领域，具体涉及一种促进牛鼻气管炎病毒复制的方法。
背景技术
牛鼻气管炎病毒(Infectious bovine rhinotracheitis virus，IBRV)是双链DNA病毒，疱疹病毒科成员，是牛的重要传染病病原；牛传染性鼻气管炎(Infectious bovinerhinotracheitis，IBR)已成为全球性疫病，给养牛业造成重大经济损失。目前IBR在我国具有较高流行率，由于临床上治疗效果并不理想，因此常用疫苗接种来预防该病。
目前商业化的常规疫苗主要有两种：灭活苗和减毒苗，如何提高疫苗产量、降低疫苗生产成本成为疫苗生产的重点难题，因此，如何促进牛鼻气管炎病毒复制，提高疫苗的生产效率，是现有技术有待解决的技术问题。
发明内容
本部分的目的在于概述本发明的实施例的一些方面以及简要介绍一些较佳实施例。在本部分以及本申请的说明书摘要和发明名称中可能会做些简化或省略以避免使本部分、说明书摘要和发明名称的目的模糊，而这种简化或省略不能用于限制本发明的范围。
因此，本发明克服现有技术中存在的不足，提供一种促进牛鼻气管炎病毒复制的方法。
为解决上述技术问题，本发明提供了如下技术方案：一种促进牛鼻气管炎病毒复制的方法，其包括，用低温常压等离子体发生器照射牛肾细胞培养基，将经过照射处理的所述培养基加入牛肾细胞中，并加入牛鼻气管炎病毒孵育。
作为本发明所述促进牛鼻气管炎病毒复制的方法的一种优选方案：所述培养基包括DMEM培养基。
作为本发明所述促进牛鼻气管炎病毒复制的方法的一种优选方案：所述用低温常压等离子体发生器照射DMEM培养基，控制氦气流量为1slm/min，通过调节变压器控制高频电源的输出电压为0.96～1.24kV。
作为本发明所述促进牛鼻气管炎病毒复制的方法的一种优选方案：所述用低温常压等离子体发生器照射DMEM培养基，包括将所述DMEM培养基放在低温常压等离子体发生器正下方，等离子体束流尾端与DMEM培养基的距离控制为1cm。
作为本发明所述促进牛鼻气管炎病毒复制的方法的一种优选方案：所述照射，时间为2min。
作为本发明所述促进牛鼻气管炎病毒复制的方法的一种优选方案：还包括，在用低温常压等离子体发生器照射牛肾细胞培养基的前一天将牛肾细胞铺于六孔板中，每孔细胞数量50万。
作为本发明所述促进牛鼻气管炎病毒复制的方法的一种优选方案：所述将经过照射处理的培养基加入牛肾细胞中，其中，每孔加入1mL经过照射处理的所述培养基。
作为本发明所述促进牛鼻气管炎病毒复制的方法的一种优选方案：所述加入牛鼻气管炎病毒孵育，包括，加入牛鼻气管炎病毒后放入37℃培养箱中孵育，时间为1h。
作为本发明所述促进牛鼻气管炎病毒复制的方法的一种优选方案：还包括，加入牛鼻气管炎病毒孵育后，用含2％胎牛血清的1640培养所述牛肾细胞，继续培养至细胞全部脱落，收集所述牛肾细胞。
本发明的有益效果：本发明通过等离子体间接处理细胞，处理均匀且强度可控。本发明处理时间只需2min，操作简单、快速，处理后的DMEM培养基与牛鼻气管炎病毒和牛肾细胞一同孵育1h就能显著提高牛鼻气管炎病毒在牛肾细胞中的复制，得到的高浓度牛鼻气管炎病毒经灭活处理可用于疫苗生产，显著提高疫苗生产效率。
附图说明
为了更清楚地说明本发明实施例的技术方案，下面将对实施例描述中所需要使用的附图作简单地介绍，显而易见地，下面描述中的附图仅仅是本发明的一些实施例，对于本领域普通技术人员来讲，在不付出创造性劳动性的前提下，还可以根据这些附图获得其它的附图。其中：
图1为本发明低温常压等离子体处理培养基，孵育细胞的流程图。
图2为牛鼻气管炎病毒荧光定量PCR检测结果图，0s为对照组，120s表示低温常压等离子体处理时间为2min。
图3为牛鼻气管炎病毒TCID50法测定结果图。0s为对照组，120s表示低温常压等离子体处理时间为2min。
具体实施方式
为使本发明的上述目的、特征和优点能够更加明显易懂，下面结合具体实施例对本发明的具体实施方式做详细的说明。
在下面的描述中阐述了很多具体细节以便于充分理解本发明，但是本发明还可以采用其他不同于在此描述的其它方式来实施，本领域技术人员可以在不违背本发明内涵的情况下做类似推广，因此本发明不受下面公开的具体实施例的限制。
其次，此处所称的“一个实施例”或“实施例”是指可包含于本发明至少一个实现方式中的特定特征、结构或特性。在本说明书中不同地方出现的“在一个实施例中”并非均指同一个实施例，也不是单独的或选择性的与其他实施例互相排斥的实施例。
实施例1：
细胞铺板：提前一天将长满的牛肾细胞用0.25％的胰酶消化离心重悬后计数，铺于六孔板中，每孔50万细胞。
向干净的12孔板中加入空白的待处理的DMEM培养基，每孔1mL，放在低温常压等离子体发生器正下方，等离子体束流尾端与培养基的距离(D)控制为1cm，喷射口垂直对准12孔板小孔的中央，控制氦气流量(F)为1slm/min，通过调节变压器控制高频电源的输出电压(U)为0.96～1.24KV，等离子体照射DMEM培养基2min。将单独照射后的培养基转入离心管中，按照每毫升培养基加入2uL的量加入牛鼻气管炎病毒。混匀。将6孔板中培养基轻轻吸出，加入上述含病毒培养基，每孔1mL；对照组加入1mL含病毒的未处理的DMEM培养基。将上述6孔板放入37℃培养箱中孵育1h后，将6孔板拿出换成含2％胎牛血清的1640维持液(图1)，再继续放入培养箱中培养至细胞全部脱落，收集对照组和实验组的培养液。一部分用荧光定量PCR(qPCR)检测病毒含量，一部分用TCID50法测定病毒滴度。
荧光定量PCR(qPCR)检测：采用天根病毒基因组DNA/RNA提取试剂盒(DP315)提取培养液病毒基因组DNA，提取步骤参照试剂盒说明书。将上述基因组DNA作为荧光定量PCR检测的模板，进行实时定量PCR检测。荧光定量PCR检测体系为10uL：5uLSYBR Green PCRMaster Mix，上、下游引物各0.4uL，煮沸后的上清模板2uL，ddH2O2uL。反应条件为：95℃预变性30s，95℃10s，60℃30s，72℃20s，40个循环，溶解曲线分析条件为：95℃15s，60℃30s，95℃15s。结果显示，低温常压等离子体照射后的培养基与牛鼻气管炎病毒和牛肾细胞一同孵育1h后，qPCR法检测牛鼻气管炎病毒产量较对照组提高2.6倍(图2，0s为对照组，120s表示低温常压等离子体处理时间为2min)。
TCID50法测定病毒滴度：提前一天将牛肾细胞消化铺板至96孔板中，每孔1万细胞。37℃培养待用。参考测定方法，将上述收集的对照组与实验组的病毒液体用1640培养基10倍梯度稀释6个梯度。吸去96孔板中的培养液，将上述两组不同稀释度的病毒加入孔中，每个稀释度8个重复，一同孵育1h后换成维持液。每天观察记录细胞病变(CPE)产生情况。观察CPE，计算病毒滴度：
按照Reed-Muench两氏法以每列所有平行中出现CPE样品达到50％作为分界线，取刚好病变率超过50％和低于50％的列做计算：距离比例＝(高于50％病变率的百分数-50％)/(高于50％病变率的百分数-低于50％病变率的百分数)lgTCID50＝距离比例×稀释度对数之间的差+高于50％病变率的稀释度的对数，结果显示，通过TCID50法测定病毒滴度与qPCR法结果基本一致，低温常压等离子处理后与对照相比病毒滴度提高2.19倍(图3，0s为对照组，120s表示低温常压等离子体处理时间为2min)。
本发明通过使用低温等离子体发生装置电离氦气来产生等离子体射流处理培养基。在这个处理过程中，等离子体射流暴露在空气中并与培养基接触，一些活性物质通过等离子体射流进入到培养基中，在培养基中产生大量的活性氧和活性氮。向处理后的培养加入病毒，再将混合液加入细胞一同孵育，发现这种经过处理的培养基对能够促进牛鼻气管炎病毒在牛肾细胞(MDBK细胞)的复制。相对于直接用低温常压等离子体处理细胞存在的安全隐患，本发明间接的处理方法更安全可靠，操作方便。
本发明通过等离子体间接处理细胞，处理均匀且强度可控。本发明处理时间只需2min，操作简单、快速，处理后的DMEM培养基与牛鼻气管炎病毒和牛肾细胞一同孵育1h就能显著提高牛鼻气管炎病毒在牛肾细胞中的复制，得到的高浓度牛鼻气管炎病毒经灭活处理可用于疫苗生产，显著提高疫苗生产效率。
应说明的是，以上实施例仅用以说明本发明的技术方案而非限制，尽管参照较佳实施例对本发明进行了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的精神和范围，其均应涵盖在本发明的权利要求范围当中。
Claims (5)
1.一种促进牛鼻气管炎病毒复制的方法，其特征在于：包括，用低温常压等离子体发生器照射牛肾细胞DMEM培养基，将经过照射处理的培养基加入牛肾细胞中，并加入牛鼻气管炎病毒孵育；
用低温常压等离子体发生器照射DMEM培养基，控制氦气流量为1slm，通过调节变压器控制高频电源的输出电压为0.96～1.24kV；
用低温常压等离子体发生器照射DMEM培养基，包括将所述DMEM培养基放在低温常压等离子体发生器正下方，等离子体束流尾端与DMEM培养基的距离控制为1cm；
所述照射，时间为2min。
2.如权利要求1所述的方法，其特征在于：还包括，在用低温常压等离子体发生器照射牛肾细胞DMEM培养基的前一天将牛肾细胞铺于六孔板中，每孔细胞数量50万。
3.如权利要求2所述的方法，其特征在于：所述将经过照射处理的培养基加入牛肾细胞中，其中，每孔加入1mL经过照射处理的培养基。
4.如权利要求3所述的方法，其特征在于：所述加入牛鼻气管炎病毒孵育，包括，加入牛鼻气管炎病毒后放入37℃培养箱中孵育，时间为1h。
5.如权利要求1、3、4中任一所述的方法，其特征在于：还包括，加入牛鼻气管炎病毒孵育后，用含2％胎牛血清的1640培养所述牛肾细胞，继续培养至细胞全部脱落，收集所述牛肾细胞。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810377315.6A CN108441483B (zh) | 2018-04-25 | 2018-04-25 | 一种促进牛鼻气管炎病毒复制的方法 |
| US16/388,823 US11530390B2 (en) | 2018-04-25 | 2019-04-18 | Method for promoting replication of bovine rhinotracheitis viruses using cold atmospheric plasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810377315.6A CN108441483B (zh) | 2018-04-25 | 2018-04-25 | 一种促进牛鼻气管炎病毒复制的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108441483A CN108441483A (zh) | 2018-08-24 |
| CN108441483B true CN108441483B (zh) | 2021-09-10 |
Family
ID=63201556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810377315.6A Active CN108441483B (zh) | 2018-04-25 | 2018-04-25 | 一种促进牛鼻气管炎病毒复制的方法 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US11530390B2 (zh) |
| CN (1) | CN108441483B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453381A (zh) * | 2018-10-22 | 2019-03-12 | 安徽医科大学第二附属医院 | 一种抑制皮肤恶性肿瘤细胞生长的低温等离子体激活液 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6518013B1 (en) * | 1993-06-07 | 2003-02-11 | Trimeris, Inc. | Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission |
| CN101773667A (zh) * | 2010-01-28 | 2010-07-14 | 洛阳普莱柯生物工程有限公司 | 一种猪圆环病毒ii型疫苗制备 |
| CN107201333A (zh) * | 2016-03-16 | 2017-09-26 | 金宇保灵生物药品有限公司 | 可悬浮培养的牛肾细胞在病毒培养及疫苗生产的应用 |
| EP3296398A1 (en) * | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
-
2018
- 2018-04-25 CN CN201810377315.6A patent/CN108441483B/zh active Active
-
2019
- 2019-04-18 US US16/388,823 patent/US11530390B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6518013B1 (en) * | 1993-06-07 | 2003-02-11 | Trimeris, Inc. | Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission |
| EP3296398A1 (en) * | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| CN101773667A (zh) * | 2010-01-28 | 2010-07-14 | 洛阳普莱柯生物工程有限公司 | 一种猪圆环病毒ii型疫苗制备 |
| CN107201333A (zh) * | 2016-03-16 | 2017-09-26 | 金宇保灵生物药品有限公司 | 可悬浮培养的牛肾细胞在病毒培养及疫苗生产的应用 |
Non-Patent Citations (4)
| Title |
|---|
| BHV-1 induced oxidative stress contributes to mitochondrial dysfunction in MDBK cells;Liqian Zhu et al.;《VETERINARY RESEARCH》;20160322;第47卷(第47期);摘要、第1页右栏第3段 * |
| Hydrogen Peroxide Induce Human Cytomegalovirus Replication through the Activation of p38-MAPK Signaling Pathway;Jun Xiao et al.;《Viruses》;20150604;第7卷;第2816-2833页 * |
| 低温常压等离子体对牛鼻气管炎病毒产量的影响及其机理研究;孙曼曼;《中国优秀硕士学位论文全文数据库 农业科技辑》;20191215(第12期);第D050-170页 * |
| 牛传染性鼻气管炎病毒的增殖培养及纯化;王晶钰等;《中国畜牧杂志》;20091231;第360页左栏第1.1.2、1.2.1.1-1.2.1.2节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108441483A (zh) | 2018-08-24 |
| US11530390B2 (en) | 2022-12-20 |
| US20190330598A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zheng et al. | Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome | |
| CN106399377A (zh) | 一种基于CRISPR/Cas9高通量技术筛选药物靶点基因的方法 | |
| CN108441483B (zh) | 一种促进牛鼻气管炎病毒复制的方法 | |
| CN104673937A (zh) | 一种猪脑心肌炎病毒纳米pcr检测试剂盒及其检验方法 | |
| CN102296073A (zh) | 锌指核酸酶定点敲除Myostatin基因特异靶位点 | |
| CN103627699A (zh) | 一种适用于dna扩增技术的中药材基因组dna提取方法 | |
| CN105176936A (zh) | 复制耐受型的西门利克森林病毒的亚克隆及制备方法和应用 | |
| CN101967524B (zh) | 实时荧光定量rt-pcr检测东部马脑炎病毒和西部马脑炎病毒的试剂盒 | |
| CN106399591B (zh) | I型鸭肝炎病毒和鸭瘟病毒一步法pcr检测方法 | |
| CN106520828A (zh) | 一种玉米整株trv载体介导病毒诱导基因沉默方法 | |
| Wang et al. | In vitro RNA interference targeting the DNA polymerase gene inhibits orf virus replication in primary ovine fetal turbinate cells | |
| Liu et al. | Tolerance of Senecavirus A to mutations in its kissing-loop or pseudoknot structure computationally predicted in 3′ untranslated region | |
| Cheung et al. | Production of single‐cycle infectious SARS‐CoV‐2 through a trans‐complemented replicon | |
| CN105200059A (zh) | 靶向抑制小鼠UCP2基因表达的siRNA及其表达载体的构建 | |
| Zhao et al. | Inhibiting cyprinid herpesvirus-3 replication with CRISPR/Cas9 | |
| CN109679952B (zh) | 一种抗PRRSV感染的猪源miR-c89及其应用 | |
| CN108055827A (zh) | 高成长肠病毒71型病毒株及其疫苗 | |
| CN107889772A (zh) | 一种基于等离子照射的促进养殖鱼生长方法及装置 | |
| CN112522216A (zh) | 重组腺相关病毒AAV-gas6及应用 | |
| Seemayer et al. | Analysis of minimal functions of simian virus 40 II. Enhancement of oncogenic transformation in vitro by UV irradiation | |
| CN112933066A (zh) | 抑制剂kn-93抑制猪繁殖与呼吸综合征病毒体外感染的方法及应用 | |
| CN107723279B (zh) | 一种缺陷型腺病毒AdC68-GP的培养方法 | |
| EP3849601A1 (en) | Poliovirus receptor (pvr/cd155) knockout cells derived from rd (human rhabdomyosarcoma) cell line by crispr | |
| CN107447045A (zh) | 一种小反刍动物慢病毒的病原学检测试剂盒 | |
| Mokhtari et al. | Developing an Antiviral Drug Screening System for Anti-Bovine Viral Diarrhea Virus (BVDV) Therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |